戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 thout the presence of any other cytotoxic or cytostatic agent.
2 autophagy, suggesting it may be a less toxic cytostatic agent.
3 reast cancer subtype, epithelial origin, and cytostatic agent.
4  models for the treatment effect of targeted cytostatic agents.
5 II trials may not be appropriate for testing cytostatic agents.
6 dependent manner) may not be appropriate for cytostatic agents.
7 s for modifying trial designs to accommodate cytostatic agents.
8 onse to a broad range of cell cycle specific cytostatic agents.
9 to be superior to FDA-approved SSTR2-binding cytostatic agents.
10 s in the early development stage of targeted cytostatic agents.
11 ns for the early development of target-based cytostatic agents.
12 esign to evaluate the activity of a putative cytostatic agent, acknowledging heterogeneity of tumor g
13 etagal-treated vessels (P<0.05), whereas the cytostatic agent Ad-p21 decreased lesion size by 58% (P<
14 ate that in SH-SY5Y cells, suramin acts as a cytostatic agent and can block IGF-II-dependent cell gro
15 ory nerve action potential amplitude for all cytostatic agents and a moderate reduction of nerve cond
16 al trials suggested that sorafenib acts as a cytostatic agent, as many patients experienced prolonged
17                 Although mTOR inhibitors are cytostatic agents, best used in combination therapy, we
18 dicate that the combination of cytotoxic and cytostatic agents could represent an important modality
19 -(2-hydroxypropyl)methacrylamide (HPMA) with cytostatic agent doxorubicin attached via stimuli-sensit
20 e progression) to evaluate the efficacy of a cytostatic agent in a phase II trial is more relevant th
21 onged by subsequent treatment with the three cytostatic agents in all HCCs may be of clinical importa
22 is a growth suppressive program activated by cytostatic agents in some cancer cells.
23 intenance strategies with both cytotoxic and cytostatic agents in women who achieve a secondary respo
24  As known and described in detail, the three cytostatic agents inhibit different processes necessary
25 ongly suggest that the use of rapamycin as a cytostatic agent may be an efficient tool for the treatm
26                                         Such cytostatic agents may offer clinical benefits for patien
27 n colon carcinoma (HCC) cells, the effect of cytostatic agents reported to inhibit HCC growth [IFN-al
28                                     Over 300 cytostatic agents selected from the National Cancer Inst
29  regions of a tumor and release cytotoxic or cytostatic agents; several of these HAPs are currently i
30 erties have been reported previously for the cytostatic agents shown here to up-regulate beta-chemoki
31           These compounds are widely used as cytostatic agents, so this enzyme should be studied as a
32                                              Cytostatic agents targeted against angiogenesis and tumo
33                        Rapamycin is a potent cytostatic agent that arrests cells in the G1 phase of t
34 a unique combination of immunomodulatory and cytostatic agents that recondition the tumor microenviro
35     Exposure of motor neuron cultures to the cytostatic agent vincristine markedly decreased CAT leve
36 sintercalators (8, 9, 12, and 13) behaved as cytostatic agents, while the monosubstituted acridine an
37             These results suggest that novel cytostatic agents with efficacy against human prostate c